IP3 and Its Role in Signaling Pathways (G3705)

Target Name: ITPK1

NCBI ID: G3705

ITPK1

IP3 and Its Role in Signaling Pathways

Inositol 1,3,4-trisphosphate (IP3) is a crucial signaling molecule that plays a key role in various cellular processes, including intracellular signaling, ion homeostasis, and neurotransmission. IP3 is generated by the breakdown of inositol triphosphate (IP3) using the IP3 kinase, also known as IP3 kinase A or kinase A. This enzyme catalyzes the transfer of a phosphate group from the IP3 molecule to a target protein, resulting in the formation of IP3.

IP3 has been extensively studied for its potential role in various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its role in these diseases has led to the development of new therapeutic strategies, including inhibitors of IP3 kinase. In this article, we will focus on one such drug target, ITPK1 (inositol 1,3,4-trisphosphate 5/6-kinase), and its potential as a therapeutic approach for various diseases.

Structure and function

ITPK1 is a calcium ion-dependent enzyme that belongs to the IMP enzyme family. IMP enzymes play important roles within cells, including signaling, ion balance, and neurotransmission. IP3 is produced by the insertion of a phosphate group into the IP3 molecule by the IP3 enzyme.

ITPK1 is an intracellular signaling transduction molecule that participates in regulating many signaling pathways, such as cell proliferation, apoptosis, cell cycle, insulin signaling, and neurotransmission. IP3 plays a key role in these signaling processes and is the mediator of signal transmission.

The role of IP3 in cancer

The role of IP3 in cancer has been extensively studied. Many studies have shown that IP3 plays an important role in tumor growth and progression. The increase of IP3 can promote the proliferation and invasion of tumor cells, while the decrease of IP3 can inhibit the growth and metastasis of tumor cells.

For example, some studies have shown that the up-regulation of IP3 expression in breast cancer is positively correlated with the progression and invasion ability of breast cancer. In addition, inhibition of IP3 has also been shown to significantly inhibit the invasion and metastasis of cancers such as lung cancer, prostate cancer, and colon cancer.

The role of IP3 in neurodegenerative diseases

The role of IP3 in neurodegenerative diseases has also been extensively studied. For example, abnormal accumulation of IP3 in the brain has been linked to neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis.

Studies have shown that abnormal accumulation of IP3 in the brain can lead to neuron loss and neural circuit damage, thereby exacerbating the development of neurodegenerative diseases. In addition, inhibition of IP3 has also been shown to improve cognitive function and neurological recovery in patients with neurodegenerative diseases.

The role of IP3 in metabolic diseases

The role of IP3 in metabolic diseases has also been extensively studied. For example, abnormal increases in IP3 in metabolic diseases such as diabetes, obesity, and cardiovascular disease have been shown to be associated with disease development and progression.

Studies have shown that an increase in IP3 can lead to increased blood sugar and adipose tissue damage in diabetic patients, while a decrease in IP3 can improve blood sugar control and adipose tissue metabolism in diabetic patients. In addition, inhibition of IP3 has also been shown to significantly reduce body weight and blood lipid levels in patients with obesity and cardiovascular disease.

drug target

ITPK1 is a potential drug target because it plays a key role in the IP3 signaling pathway. Many studies have shown that inhibition of ITPK1 can significantly inhibit the progression of tumors, neurodegenerative diseases, and metabolic diseases.

Currently, a variety of drugs that inhibit ITPK1 activity have entered clinical research. For example, one known drug, Acyclovir, has been used to treat shingles and other viral infections. Additionally, another drug, Nifedipine, is already used to treat high blood pressure and angina.

In the future, ITPK1, as a drug target, is expected to provide new therapeutic strategies for the treatment of tumors, neurodegenerative diseases and metabolic diseases.

Protein Name: Inositol-tetrakisphosphate 1-kinase

Functions: Kinase that can phosphorylate various inositol polyphosphate such as Ins(3,4,5,6)P4 or Ins(1,3,4)P3 (PubMed:11042108, PubMed:8662638). Phosphorylates Ins(3,4,5,6)P4 at position 1 to form Ins(1,3,4,5,6)P5 (PubMed:11042108). This reaction is thought to have regulatory importance, since Ins(3,4,5,6)P4 is an inhibitor of plasma membrane Ca(2+)-activated Cl(-) channels, while Ins(1,3,4,5,6)P5 is not. Also phosphorylates Ins(1,3,4)P3 on O-5 and O-6 to form Ins(1,3,4,6)P4, an essential molecule in the hexakisphosphate (InsP6) pathway (PubMed:11042108, PubMed:8662638). Also acts as an inositol polyphosphate phosphatase that dephosphorylates Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4 to Ins(1,3,4)P3, and Ins(1,3,4,5,6)P5 to Ins(3,4,5,6)P4 (PubMed:17616525, PubMed:11909533). May also act as an isomerase that interconverts the inositol tetrakisphosphate isomers Ins(1,3,4,5)P4 and Ins(1,3,4,6)P4 in the presence of ADP and magnesium (PubMed:11909533). Probably acts as the rate-limiting enzyme of the InsP6 pathway. Modifies TNF-alpha-induced apoptosis by interfering with the activation of TNFRSF1A-associated death domain (PubMed:11909533, PubMed:12925536, PubMed:17616525). Plays an important role in MLKL-mediated necroptosis. Produces highly phosphorylated inositol phosphates such as inositolhexakisphosphate (InsP6) which bind to MLKL mediating the release of an N-terminal auto-inhibitory region leading to its activation. Essential for activated phospho-MLKL to oligomerize and localize to the cell membrane during necroptosis (PubMed:17616525)

The "ITPK1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ITPK1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets